Company & Sponsor Intelligence
Eisai Limited
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed0
Countries2
Therapeutic footprint
unclassified
Indexed studies
NCT01546688A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
unclassified · GermanyPHASE4
unclassified · GermanyPHASE4
NCT00692003Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
unclassified · AustraliaPHASE3
unclassified · AustraliaPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →